Targeted molecular profiles in our study, encompassing breast cancer and gynecological malignancies (pan-gyn tumors), most frequently revealed mutations in TP53, PIK3CA, BRCA1/2, and ARID1A. This evidence concerns the gene BRCA1 and breast carcinoma.